myositis and chronic immune thrombocytopenia.
A56R, viral hemagglutinin; B19R, soluble alpha/beta interferon [IFN] receptor; E3L, dsRNA-binding protein; rpo 132-ATIp4c-A27L, a region that codes for the major protein of the A-type inclusion body
(14); NA, not available.
The term hereditary inclusion body
myopathy (h-IBM) was introduced in 1993 to designate a familial form of muscle disease similar pathologically to sporadic IBM (s-IBM), except for the lack of lymphocytic mononuclear cell inflammation.
Gene for A-type inclusion body
protein is useful for a polymerase chain reaction assay to differentiate orthopoxviruses.
Summary of Bcl-2, Bcl-X, and Bax Immunoreactivity in Inclusion Body
Myositis (N = 27) Degene- Regene- Subsar- rating rating Autophagic colemmal Antibody Inflammation Fibers Fibers Vacuoles Staining Bax 26 (96) * 24 (89) 24 (89) 24 (89) 21 (78) Bcl-2 27 (100) 2 (7) 21 (78) 2 (7) 6 (22) Bcl-x 8 (30) 3 (11) 4 (15) 3 (11) 1 (4) * Values are expressed as number positive (%).
The program is currently in a Phase I/II trial at Nationwide Children's Hospital in adult patients with Becker muscular dystrophy and inclusion body
myositis, a trial funded by the foundation Parent Project Muscular Dystrophy.
a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced results from a first-in-human, multi-center, Phase 1 study of UX001 in patients with hereditary inclusion body
myopathy (HIBM) showing that UX001 was well-tolerated with an expected extended release profile on absorption after oral administration.
a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the European Medicines Agency (EMA) has granted orphan drug designations for sialic acid for the treatment of hereditary inclusion body
myopathy (HIBM) and recombinant human beta-glucuronidase for the treatment of mucopolysaccharidosis type 7 (MPS 7).
a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced that the Phase 1 study of UX001 for hereditary inclusion body
myopathy (HIBM) has been completed.
Ultragenyx' lead program, UX001, is being evaluated as a potential treatment for GNE myopathy, also known as hereditary inclusion body
The Phase I/II trial, funded by a grant from Parent Project Muscular Dystrophy, is enrolling patients with Becker muscular dystrophy and inclusion body
will inject a modified virus (vector) carrying the gene for the muscle growth-stimulating protein follistatin into the quadriceps muscles of volunteers with Becker muscular dystrophy and sporadic inclusion body